2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB2 days ago · CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will discontinue enrollment ...
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly ...
WEB1 day ago · 2seventy bio will focus exclusively on the commercialization and continued development of Abecma. Price Action: TSVT stock is down 7.65% at $4.41, and BMY stock is down 2.90% at $49.47 at last ...
2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB2 days ago · 2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study. Decision results in over $80 million in anticipated cost savings for 2seventy over the next several years and accelerates path to breakeven in 2025. Expanded 3L+ label drives re-acceleration in Abecma U.S. revenues with third quarter revenue expected to grow approximately 30% from second quarter revenue of $54 ...
BMS and 2seventy bio to discontinue enrolment in multiple …
WEB1 day ago · Thu, Sep 26, 2024, 6:32 AM 2 min read. Bristol Myers Squibb (BMS) and 2seventy bio have announced plans to discontinue enrolment of subjects in the Phase III KarMMa-9 clinical trial of Abecma ...
2seventy bio Provides Update on KarMMa-9 Study and Previews
WEB2 days ago · About 2seventy bio. Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. ... BioSpace is the digital hub for life science news and jobs. We provide essential ...
Struggling 2Seventy scraps a key cancer study | BioPharma Dive
WEB2 days ago · The decision announced Wednesday was made, in part, to help ensure 2Seventy breaks even financially next year. The biotechnology company expects ending the trial will save $80 million in the near term. 2Seventy recorded a $27 million loss from operations in the second quarter and, as of June 30, …
2seventy bio Announces New Strategic Path Forward
WEBJan 30, 2024 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Jan. 30, 2024-- 2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T therapy for multiple myeloma.
2seventy bio Announces Completion of Oncology and …
WEBApr 1, 2024 · Going forward, 2seventy bio will focus exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS).
Citing enrollment challenges, Bristol Myers and 2seventy scrap …
WEB2 days ago · Bristol and its partner 2seventy bio have decided to pull the plug on the phase 3 KarMMa-9 trial. The trial had been evaluating Abecma as a first-line maintenance treatment in patients with newly ...
2seventy bio Provides Update on KarMMa-9 Study and Previews …
WEB2 days ago · 2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal ...